Terry A. Jacobson

Terry A. Jacobson

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Terry A. Jacobson

Lipid Clinic and Cardiovascular Risk Reduction Program, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2015 in European Heart Journal
Verified
Journal Article
Open access
PDF file
ESErik S. Stroes
Erik S. Stroes
PTPaul D. Thompson
Paul D. Thompson
ACAlberto Corsini
Alberto Corsini
GVGeorgirene D. Vladutiu
Georgirene D. Vladutiu
FRFrederick J. Raal
Frederick J. Raal
LLLawrence Leiter
Lawrence Leiter
Statin-associated muscle symptoms (SAMS) are one of the principal reasons for statin non-adherence and/or discontinuation, contributing to adverse cardiovascular outcomes. This European Atherosclerosis Society (EAS) Consensus Panel overviews current understanding of the pathophysiology of statin-associated myopathy, and provides guidance for diagnosis and management of SAMS. Statin-associated myopathy, with significant elevation of serum creatine kinase (CK), is a rare but serious side effect of statins, affecting 1 per 1000 to 1 per 10 000 people on standard statin doses. Statin-associated muscle symptoms cover a broader range of clinical presentations, usually with normal or minimally elevated CK levels, with a prevalence of 7–29% in registries and observational studies. Preclinical studies show that statins decrease mitochondrial function, attenuate energy production, and alter muscle protein degradation, thereby providing a potential link between statins and muscle symptoms; controlled mechanistic and genetic studies in humans are necessary to further understanding. The Panel proposes to identify SAMS by symptoms typical of statin myalgia (i.e. muscle pain or aching) and their temporal association with discontinuation and response to repetitive statin re-challenge. In people with SAMS, the Panel recommends the use of a maximally tolerated statin dose combined with non-statin lipid-lowering therapies to attain recommended low-density lipoprotein cholesterol targets. The Panel recommends a structured work-up to identify individuals with clinically relevant SAMS generally to at least three different statins, so that they can be offered therapeutic regimens to satisfactorily address their cardiovascular risk. Further research into the underlying pathophysiological mechanisms may offer future therapeutic potential.

1 March 2015 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
TJTerry A. Jacobson
Terry A. Jacobson
MIMatthew K. Ito
Matthew K. Ito
KMKevin C. Maki
Kevin C. Maki
COCarl E. Orringer
Carl E. Orringer
HBHarold E. Bays
Harold E. Bays
WBW. Virgil Brown
W. Virgil Brown

11 April 2017 in Circulation
Verified
Journal Article
Closed access
PDF file
DSDavid S. Siscovick
David S. Siscovick
TBThomas A. Barringer
Thomas A. Barringer
AFAmanda M. Fretts
Amanda M. Fretts
JWJason Wu
Jason Wu
ALAlice H. Lichtenstein
Alice H. Lichtenstein
DMDariush Mozaffarian
Dariush Mozaffarian
Multiple randomized controlled trials (RCTs) have assessed the effects of supplementation with eicosapentaenoic acid plus docosahexaenoic acid (omega-3 polyunsaturated fatty acids, commonly called fish oils) on the occurrence of clinical cardiovascular diseases. Although the effects of supplementation for the primary prevention of clinical cardiovascular events in the general population have not been examined, RCTs have assessed the role of supplementation in secondary prevention among patients with diabetes mellitus and prediabetes, patients at high risk of cardiovascular disease, and those with prevalent coronary heart disease. In this scientific advisory, we take a clinical approach and focus on common indications for omega-3 polyunsaturated fatty acid supplements related to the prevention of clinical cardiovascular events. We limited the scope of our review to large RCTs of supplementation with major clinical cardiovascular disease end points; meta-analyses were considered secondarily. We discuss the features of available RCTs and provide the rationale for our recommendations. We then use existing American Heart Association criteria to assess the strength of the recommendation and the level of evidence. On the basis of our review of the cumulative evidence from RCTs designed to assess the effect of omega-3 polyunsaturated fatty acid supplementation on clinical cardiovascular events, we update prior recommendations for patients with prevalent coronary heart disease, and we offer recommendations, when data are available, for patients with other clinical indications, including patients with diabetes mellitus and prediabetes and those with high risk of cardiovascular disease, stroke, heart failure, and atrial fibrillation.

1 November 2015 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
TJTerry A. Jacobson
Terry A. Jacobson
KMKevin C. Maki
Kevin C. Maki
COCarl E. Orringer
Carl E. Orringer
PJPeter H. Jones
Peter H. Jones
PKPenny Kris-Etherton
Penny Kris-Etherton
WBW. Virgil Brown
W. Virgil Brown
An Expert Panel convened by the National Lipid Association previously developed a consensus set of recommendations for the patient-centered management of dyslipidemia in clinical medicine (part 1). These were guided by the principle that reducing elevated levels of atherogenic cholesterol (non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol) reduces the risk for atherosclerotic cardiovascular disease. This document represents a continuation of the National Lipid Association recommendations developed by a diverse panel of experts who examined the evidence base and provided recommendations regarding the following topics: (1) lifestyle therapies; (2) groups with special considerations, including children and adolescents, women, older patients, certain ethnic and racial groups, patients infected with human immunodeficiency virus, patients with rheumatoid arthritis, and patients with residual risk despite statin and lifestyle therapies; and (3) strategies to improve patient outcomes by increasing adherence and using team-based collaborative care.

1 January 2009 in Value in Health
Verified
Journal Article
Closed access
SKSunil Kripalani
Sunil Kripalani
JRJessica Risser
Jessica Risser
MGMargaret E. Gatti
Margaret E. Gatti
TJTerry A. Jacobson
Terry A. Jacobson

1 May 2014 in Journal of Clinical Lipidology
Verified
Journal Article
Closed access
RRRobert S. Rosenson
Robert S. Rosenson
SBSteven K. Baker
Steven K. Baker
TJTerry A. Jacobson
Terry A. Jacobson
SKStephen L. Kopecky
Stephen L. Kopecky
BPBeth A. Parker
Beth A. Parker